Sleep quality after initial chemotherapy for breast cancer

Susan L. Beck, Ann Malone Berger, Andrea M. Barsevick, Bob Wong, Katie A. Stewart, William N. Dudley

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Goals of work The goal of this study is to characterize sleep quality and quantity prior to and in the first three nights after initial chemotherapy for breast cancer. Materials and methods This study makes use of secondary analysis of data from two separate randomized clinical trials (RCT) of behavioral interventions to improve fatigue and sleep. Patients came from two comprehensive cancer centers, three clinical cancer centers, and 10 community clinics in five states. Participants were women with stage I-IIIA breast cancer treated with anthracycline and/or cyclophosphamide-based regimens. Main results Baseline data from each RCT were used in the analysis. Sixty-five percent of women self-reported poor sleep in the month preceding chemotherapy using the Pittsburgh Sleep Quality Index (PSQI) score >5. Three nights of actigraphy data indicated a wide range of sleep experience with an average of 10 awakenings and time (minutes) awake after sleep onset (WASO-M) averaging 61 min per night. The first night's sleep was the worst. There was no statistically significant relationship between self-reported poor sleep and sleep measures obtained by actigraphy. Women with poor sleep at baseline (global PSQI gt;5) had significantly lower (p<0.001) physical (PCS) and mental (MCS) health status. However, neither the PCS nor MCS was associated with any of the average actigraphy sleep parameters or night 1 parameters in the aggregated sample. Increasing age was also associated with poorer sleep. Conclusions A high percent of women with breast cancer begin chemotherapy with disturbed sleep and the initial nights after chemotherapy are characterized by sleep fragmentation that disrupts sleep maintenance. Interventions should focus on strategies to decrease the number and duration of night awakenings. Further research is needed to identify predictors of poor sleep during this time.

Original languageEnglish (US)
Pages (from-to)679-689
Number of pages11
JournalSupportive Care in Cancer
Volume18
Issue number6
DOIs
StatePublished - Jun 1 2010

Fingerprint

Sleep
Breast Neoplasms
Drug Therapy
Actigraphy
Randomized Controlled Trials
Sleep Deprivation
Anthracyclines
Cyclophosphamide
Health Status
Fatigue
Neoplasms
Mental Health
Maintenance

Keywords

  • Actigraphy
  • Breast cancer
  • Chemotherapy
  • Function
  • Neoplasm
  • Sleep

ASJC Scopus subject areas

  • Oncology

Cite this

Beck, S. L., Berger, A. M., Barsevick, A. M., Wong, B., Stewart, K. A., & Dudley, W. N. (2010). Sleep quality after initial chemotherapy for breast cancer. Supportive Care in Cancer, 18(6), 679-689. https://doi.org/10.1007/s00520-009-0662-y

Sleep quality after initial chemotherapy for breast cancer. / Beck, Susan L.; Berger, Ann Malone; Barsevick, Andrea M.; Wong, Bob; Stewart, Katie A.; Dudley, William N.

In: Supportive Care in Cancer, Vol. 18, No. 6, 01.06.2010, p. 679-689.

Research output: Contribution to journalArticle

Beck, SL, Berger, AM, Barsevick, AM, Wong, B, Stewart, KA & Dudley, WN 2010, 'Sleep quality after initial chemotherapy for breast cancer', Supportive Care in Cancer, vol. 18, no. 6, pp. 679-689. https://doi.org/10.1007/s00520-009-0662-y
Beck, Susan L. ; Berger, Ann Malone ; Barsevick, Andrea M. ; Wong, Bob ; Stewart, Katie A. ; Dudley, William N. / Sleep quality after initial chemotherapy for breast cancer. In: Supportive Care in Cancer. 2010 ; Vol. 18, No. 6. pp. 679-689.
@article{d4e859d89f7a48649f9206d35364a4aa,
title = "Sleep quality after initial chemotherapy for breast cancer",
abstract = "Goals of work The goal of this study is to characterize sleep quality and quantity prior to and in the first three nights after initial chemotherapy for breast cancer. Materials and methods This study makes use of secondary analysis of data from two separate randomized clinical trials (RCT) of behavioral interventions to improve fatigue and sleep. Patients came from two comprehensive cancer centers, three clinical cancer centers, and 10 community clinics in five states. Participants were women with stage I-IIIA breast cancer treated with anthracycline and/or cyclophosphamide-based regimens. Main results Baseline data from each RCT were used in the analysis. Sixty-five percent of women self-reported poor sleep in the month preceding chemotherapy using the Pittsburgh Sleep Quality Index (PSQI) score >5. Three nights of actigraphy data indicated a wide range of sleep experience with an average of 10 awakenings and time (minutes) awake after sleep onset (WASO-M) averaging 61 min per night. The first night's sleep was the worst. There was no statistically significant relationship between self-reported poor sleep and sleep measures obtained by actigraphy. Women with poor sleep at baseline (global PSQI gt;5) had significantly lower (p<0.001) physical (PCS) and mental (MCS) health status. However, neither the PCS nor MCS was associated with any of the average actigraphy sleep parameters or night 1 parameters in the aggregated sample. Increasing age was also associated with poorer sleep. Conclusions A high percent of women with breast cancer begin chemotherapy with disturbed sleep and the initial nights after chemotherapy are characterized by sleep fragmentation that disrupts sleep maintenance. Interventions should focus on strategies to decrease the number and duration of night awakenings. Further research is needed to identify predictors of poor sleep during this time.",
keywords = "Actigraphy, Breast cancer, Chemotherapy, Function, Neoplasm, Sleep",
author = "Beck, {Susan L.} and Berger, {Ann Malone} and Barsevick, {Andrea M.} and Bob Wong and Stewart, {Katie A.} and Dudley, {William N.}",
year = "2010",
month = "6",
day = "1",
doi = "10.1007/s00520-009-0662-y",
language = "English (US)",
volume = "18",
pages = "679--689",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Sleep quality after initial chemotherapy for breast cancer

AU - Beck, Susan L.

AU - Berger, Ann Malone

AU - Barsevick, Andrea M.

AU - Wong, Bob

AU - Stewart, Katie A.

AU - Dudley, William N.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Goals of work The goal of this study is to characterize sleep quality and quantity prior to and in the first three nights after initial chemotherapy for breast cancer. Materials and methods This study makes use of secondary analysis of data from two separate randomized clinical trials (RCT) of behavioral interventions to improve fatigue and sleep. Patients came from two comprehensive cancer centers, three clinical cancer centers, and 10 community clinics in five states. Participants were women with stage I-IIIA breast cancer treated with anthracycline and/or cyclophosphamide-based regimens. Main results Baseline data from each RCT were used in the analysis. Sixty-five percent of women self-reported poor sleep in the month preceding chemotherapy using the Pittsburgh Sleep Quality Index (PSQI) score >5. Three nights of actigraphy data indicated a wide range of sleep experience with an average of 10 awakenings and time (minutes) awake after sleep onset (WASO-M) averaging 61 min per night. The first night's sleep was the worst. There was no statistically significant relationship between self-reported poor sleep and sleep measures obtained by actigraphy. Women with poor sleep at baseline (global PSQI gt;5) had significantly lower (p<0.001) physical (PCS) and mental (MCS) health status. However, neither the PCS nor MCS was associated with any of the average actigraphy sleep parameters or night 1 parameters in the aggregated sample. Increasing age was also associated with poorer sleep. Conclusions A high percent of women with breast cancer begin chemotherapy with disturbed sleep and the initial nights after chemotherapy are characterized by sleep fragmentation that disrupts sleep maintenance. Interventions should focus on strategies to decrease the number and duration of night awakenings. Further research is needed to identify predictors of poor sleep during this time.

AB - Goals of work The goal of this study is to characterize sleep quality and quantity prior to and in the first three nights after initial chemotherapy for breast cancer. Materials and methods This study makes use of secondary analysis of data from two separate randomized clinical trials (RCT) of behavioral interventions to improve fatigue and sleep. Patients came from two comprehensive cancer centers, three clinical cancer centers, and 10 community clinics in five states. Participants were women with stage I-IIIA breast cancer treated with anthracycline and/or cyclophosphamide-based regimens. Main results Baseline data from each RCT were used in the analysis. Sixty-five percent of women self-reported poor sleep in the month preceding chemotherapy using the Pittsburgh Sleep Quality Index (PSQI) score >5. Three nights of actigraphy data indicated a wide range of sleep experience with an average of 10 awakenings and time (minutes) awake after sleep onset (WASO-M) averaging 61 min per night. The first night's sleep was the worst. There was no statistically significant relationship between self-reported poor sleep and sleep measures obtained by actigraphy. Women with poor sleep at baseline (global PSQI gt;5) had significantly lower (p<0.001) physical (PCS) and mental (MCS) health status. However, neither the PCS nor MCS was associated with any of the average actigraphy sleep parameters or night 1 parameters in the aggregated sample. Increasing age was also associated with poorer sleep. Conclusions A high percent of women with breast cancer begin chemotherapy with disturbed sleep and the initial nights after chemotherapy are characterized by sleep fragmentation that disrupts sleep maintenance. Interventions should focus on strategies to decrease the number and duration of night awakenings. Further research is needed to identify predictors of poor sleep during this time.

KW - Actigraphy

KW - Breast cancer

KW - Chemotherapy

KW - Function

KW - Neoplasm

KW - Sleep

UR - http://www.scopus.com/inward/record.url?scp=77953619775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953619775&partnerID=8YFLogxK

U2 - 10.1007/s00520-009-0662-y

DO - 10.1007/s00520-009-0662-y

M3 - Article

C2 - 19521723

AN - SCOPUS:77953619775

VL - 18

SP - 679

EP - 689

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 6

ER -